Arca Biopharma | ABIO - Selling And Administration Expenses


Arca Biopharma reported $2.23M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Alterity Therapeutics Limited AUD 1.45M 703.96K Dec/2025
Amgen USD 1.58B 354M Mar/2026
Arca Biopharma USD 2.23M 1.08M Dec/2025
Biogen USD 554.3M 128.2M Mar/2026
Brainstorm Cell Therapeutics USD 1.39M 326K Dec/2025
Bristol-Myers Squibb USD 1.62B 564M Mar/2026
Capricor Therapeutics USD 1.92M 446.47K Dec/2025
Cipla INR 13.25B 101.8M Dec/2025
Clal Biotechnology ILS 3.31M 513K Dec/2022
Compugen USD 2.43M 222K Mar/2026
CSL USD 1.23B 498M Dec/2025
Cytokinetics USD 104.9M 13.17M Mar/2026
Daiichi Sankyo JPY 228.23B 39.15B Dec/2025
Gilead Sciences USD 1.45B 326M Mar/2026
GlaxoSmithKline GBP 2.12B 558M Mar/2026
Grifols EUR 320.45M 12.65M Dec/2025
Laboratory Of America USD 551M 12.4M Mar/2026
Myriad Genetics USD 122.3M 6.7M Dec/2025
Otsuka Holdings JPY 259.49B 18.81B Mar/2026
Pfizer USD 2.92B 1.16B Mar/2026
United Therapeutics USD 156.6M 34M Mar/2026